The FDA cleared AbbVie’s next-generation Parkinson’s therapy, tavapadon, branded as Juvmo, expanding treatment options for dopamine-agonist–responsive symptoms. The approval marks a regulatory milestone for AbbVie’s Parkinson’s franchise and follows increased competitive focus on improving tolerability versus older dopamine agonists. The clearance also underscores how manufacturers are positioning “next-gen” dopaminergic drugs to reduce side-effect burdens while maintaining symptom control for patients with Parkinson’s disease. AbbVie’s launch readiness will be the near-term focus as the company scales prescribing and payer conversations.